Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
02-27-2024
– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome –
– First patient dosed in KOMET-008 trial of ziftomenib in combination with additional standards of care, including gilteritinib, FLAG-IDA and LDAC, in AML –
– Completion of enrollment in registration-directed trial of ziftomenib in NPM1-m AML anticipated by mid-2024 –
–
– Management to host webcast and conference call today at
“Given its best-in-class safety and efficacy profile as well as optimal pharmaceutical properties, we believe ziftomenib is well positioned to become a cornerstone of therapy for patients with acute leukemias,” said
Recent Highlights
- Encouraging safety and tolerability profile for ziftomenib in combination with 7+3 and ven/aza – In
January 2024 , Kura reported preliminary clinical data from the first 20 patients in KOMET-007, a Phase 1 dose-escalation trial of ziftomenib in combination with standards of care, including cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza), in patients with NPM1-mutant (NPM1-m) and KMT2A-rearranged (KMT2A-r) AML. The first 20 patients were enrolled betweenJuly 2023 andNovember 2023 and included five newly diagnosed patients with adverse risk NPM1-m or KMT2A-r AML and 15 patients with refractory/relapsed (R/R) NPM1-m or KMT2A-r AML. Continuous daily dosing of ziftomenib at 200 mg was well tolerated, and the safety profile was consistent with features of underlying disease and backbone therapies. No differentiation syndrome events of any grade were reported, and no dose-limiting toxicities, evidence of QTc prolongation, drug-drug interactions or additive myelosuppression were observed. - Encouraging evidence of clinical activity for ziftomenib combinations in NPM1-m and KMT2A-r AML – As of the data cutoff on
January 11, 2024 , all five newly diagnosed patients treated with ziftomenib and 7+3 achieved a complete remission with full count recovery, for a complete remission (CR) rate of 100%. The overall response rate (ORR) among the 15 R/R patients treated with ziftomenib and ven/aza was 53%, including a 40% ORR in the 10 patients who had received prior venetoclax. The CR/CRh (CR with partial hematologic recovery) rate among the nine R/R patients who were menin inhibitor naïve was 56%. As of the data cutoff, 16 of the first 20 patients remained on trial, including all 11 NPM1-mutant patients. To date, enrollment at the 400 mg dose of ziftomenib is ongoing in the R/R ven/aza cohorts and in the frontline NPM1-mutant 7+3 cohort. - First patient dosed in KOMET-008 trial of ziftomenib in combination with additional standards of care in AML – Yesterday, Kura announced dosing of the first patient in its KOMET-008 trial of ziftomenib in combination with the FLT3 inhibitor gilteritinib, FLAG-IDA or LDAC for the treatment of relapsed/refractory NPM1-m or KMT2A-r AML. Roughly half of patients with relapsed or refractory hNPM1-mutant AML have co-occurring FLT3 mutations, and the prognosis for these patients is poor. Preclinical data for ziftomenib in combination with FLT3 inhibitors demonstrate strong synergistic effects compared to either single agent alone.
- Completion of enrollment in registration-directed trial of ziftomenib in NPM1-m AML anticipated by mid-2024 – The KOMET-001 registration-directed trial of ziftomenib in NPM1-m R/R AML is expected to enroll a total of 85 patients in the
U.S. andEurope . In the Phase 1 trial, ziftomenib demonstrated a 35% CR rate and 45% overall response rate in 20 patients with NPM1-mutant AML treated at the recommended Phase 2 dose (RP2D). NPM1-mutant AML accounts for approximately 30% of new AML cases annually and represents a disease of significant unmet need for which no approved targeted therapy exists. - Addressing the continuum of care for patients with acute leukemias– Kura remains committed to developing new treatment options across the continuum of care for patients with acute leukemias, where poor outcomes and significant unmet medical need remain. In
December 2023 , the Company announced that ziftomenib was selected by theLeukemia & Lymphoma Society for the Pediatric Acute Leukemia (PedAL) Master Clinical Trial. As part of the study, ziftomenib will be evaluated in combination with chemotherapy in pediatric patients with R/R KMT2A-r, NPM1-m or NUP98-rearranged acute leukemia. In addition, Kura recently began dosing with ziftomenib in patients with R/R KMT2A-r acute lymphoblastic leukemia, a relatively small population with a large unmet medical need. - Positive results from registration-directed trial of tipifarnib in HRAS-mutant HNSCC – In
October 2023 , Kura presented positive results from its AIM-HN registration-directed trial of tipifarnib as a monotherapy in patients with HRAS-mutant head and neck squamous cell carcinoma (HNSCC). The Company continues to evaluate tipifarnib in combination with alpelisib in patients with PIK3CA-dependent HNSCC as part of its ongoing KURRENT-HN dose-escalation trial. - Dose escalation continues in first-in-human trial of KO-2806 – In
October 2023 , Kura announced that the first patient was dosed in its FIT-001 Phase 1 dose-escalation trial of its next-generation FTI, KO-2806. Concurrent with dose escalation as a monotherapy in the FIT-001 trial, the Company also plans to evaluate KO-2806 in dose-escalation combination cohorts with cabozantinib in clear cell renal cell carcinoma (ccRCC) and with adagrasib in KRASG12C-mutated non-small cell lung cancer (NSCLC). - Preclinical data support clinical combinations of KO-2806 with targeted therapies – In
October 2023 , Kura presented preclinical data supporting its rationale to combine KO-2806 with cabozantinib in ccRCC and with adagrasib in KRASG12C-mutated NSCLC. The new findings illustrate the potential for FTIs to drive enhanced antitumor activity and address mechanisms of innate and adaptive resistance to targeted therapies such as tyrosine kinase inhibitors and KRAS inhibitors. - Clinical collaboration with Mirati to evaluate KO-2806 and adagrasib in KRASG12C-mutated NSCLC – In
November 2023 , Kura announced a clinical collaboration and supply agreement with Mirati Therapeutics to evaluate the combination of KO-2806 and adagrasib in patients with KRASG12C-mutated NSCLC. Kura anticipates dosing the first patients with KO-2806 and adagrasib in KRASG12C-mutated NSCLC by mid-2024.
Financial Results
- Research and development (R&D) expenses for the fourth quarter of 2023 were
$32.5 million , compared to$22.7 million for the fourth quarter of 2022. R&D expenses for the full year 2023 were$115.2 million , compared to$92.8 million for the prior year. - General and administrative (G&A) expenses for the fourth quarter of 2023 were
$14.2 million , compared to$12.5 million for the fourth quarter of 2022. G&A expenses for the full year 2023 were$50.6 million , compared to$47.1 million for the prior year. - Net loss for the fourth quarter of 2023 was
$42.8 million , compared to a net loss of$33.1 million for the fourth quarter of 2022. Net loss for the full year 2023 was$152.6 million , compared to a net loss of$135.8 million for the prior year. - Net loss for the fourth quarter and full year 2023 included non-cash, share-based compensation expense of
$7.2 million and$28.1 million , respectively. This compares to$6.8 million and$26.3 million for the same periods in 2022. - As of
December 31, 2023 , Kura had cash, cash equivalents and short-term investments of$424.0 million , compared to$438.0 million as ofDecember 31, 2022 . - Pro forma for
$146 million in approximate net proceeds from the company’s private placement completed inJanuary 2024 , Kura had$570 million in cash, cash equivalents and short-term investments atDecember 31, 2023 . - Based on its operating plan, management expects that cash, cash equivalents and short-term investments will fund current operations into 2027.
Forecasted Milestones
- Initiate the post-transplant maintenance program for ziftomenib in the first quarter of 2024.
- Complete enrollment of 85 patients in the KOMET-001 registration-directed trial of ziftomenib in NPM1-m AML by mid-2024.
- Initiate an expansion cohort evaluating ziftomenib as a monotherapy in patients who have neither NPM1-mutant nor KMT2A-rearranged AML by mid-2024.
- Determine the RP2D for ziftomenib in combination with ven/aza and initiate dose validation/expansion in frontline AML by mid-2024.
- Determine the RP2D for ziftomenib in combination with 7+3 by mid-2024.
- Dose the first patients in the FIT-001 dose-escalation trial of KO-2806 in combination with cabozantinib in ccRCC by mid-2024.
- Dose the first patients in the FIT-001 dose-escalation trial of KO-2806 in combination with adagrasib in KRASG12C-mutated NSCLC by mid-2024.
- Complete enrollment of two expansion cohorts to support determination of the optimal biologically active dose for tipifarnib in combination with alpelisib by the end of 2024.
Conference Call and Webcast
Kura’s management will host a webcast and conference call at
About
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Kura’s product candidates, ziftomenib, tipifarnib and KO-2806, progress and expected timing of Kura’s drug development programs and clinical trials and submission of regulatory filings, the presentation of data from clinical trials, plans regarding regulatory filings and future clinical trials, the regulatory approval path for tipifarnib, the strength of Kura’s balance sheet and the sufficiency of cash, cash equivalents and short-term investments to fund its current operating plan to 2027. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, applications and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the
| Statements of Operations Data | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| (in thousands, except per share data) | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development | $ | 32,533 | $ | 22,668 | $ | 115,235 | $ | 92,812 | ||||||||
| General and administrative | 14,229 | 12,488 | 50,569 | 47,053 | ||||||||||||
| Total operating expenses | 46,762 | 35,156 | 165,804 | 139,865 | ||||||||||||
| Other income, net | 3,976 | 2,042 | 13,173 | 4,025 | ||||||||||||
| Net loss | $ | (42,786 | ) | $ | (33,114 | ) | $ | (152,631 | ) | $ | (135,840 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.55 | ) | $ | (0.49 | ) | $ | (2.08 | ) | $ | (2.03 | ) | ||||
| Weighted average number of shares used in computing net loss per share, basic and diluted |
77,337 | 67,781 | 73,229 | 66,990 | ||||||||||||
| Balance Sheet Data | |||||||||
| (unaudited) | |||||||||
| (in thousands) | |||||||||
| 2023 | 2022 | ||||||||
| Cash, cash equivalents and short-term investments | $ | 423,957 | $ | 437,985 | |||||
| Working capital | 397,218 | 422,369 | |||||||
| Total assets | 448,935 | 456,306 | |||||||
| Long-term liabilities | 16,399 | 11,971 | |||||||
| Accumulated deficit | (721,439 | ) | (568,808 | ) | |||||
| Stockholders’ equity | 397,273 | 420,278 | |||||||
Contacts
Investors:
Executive Vice President, Investor Relations & Corporate Communications
(858) 500-8833
pete@kuraoncology.com
Media:
Associate Director, Investor Relations & Corporate Communications
(858) 500-8822
alexandra@kuraoncology.com
Source: Kura Oncology, Inc.